Vaccine biotechnology company Novavax (NASDAQ:NVAX) beat Wall Street’s revenue expectations in Q3 CY2025, but sales fell by 16.6% year on year to $70.45 million. The company expects the full year’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback